Results 61 to 70 of about 10,523 (190)

Pro-protein convertase subtilisin/kexin type 9 promotes intestinal tumor development by activating Janus kinase 2/signal transducer and activator of transcription 3/SOCS3 signaling in Apc mice

International Journal of Immunopathology and Pharmacology, 2021
Introduction Pro-protein convertase subtilisin/kexin type 9 (PCSK9) regulates lipoprotein homeostasis in humans. Evolocumab is a selective PCSK9 inhibitor that can reduce low-density lipoprotein cholesterol (LDLC) level and decrease hypercholesterolemia.
Kai Yang, Jie Zhu, Huan-hua Luo, Shu-wen Yu, Lu Wang   +4 more
doaj   +1 more source

PCSK9 inhibitors in the prevention of cardiovascular disease [PDF]

Journal of Thrombosis and Thrombolysis, 2016
Reducing plasma levels of low-density lipoprotein cholesterol (LDL-C) remains the cornerstone in the primary and secondary prevention of cardiovascular disease. However, lack of efficacy and adverse effects mean that a substantial proportion of patients fail to achieve acceptable LDL-C levels with currently available lipid-lowering drugs. Over the last
Latimer, James, Batty, Jonathan A., Neely, R. Dermot G., Kunadian, Vijay   +3 more
openaire   +2 more sources

FURIN induces vascular endothelial cell death and efferocytosis through enzymatic cleavage of thrombospondin‐1

The Journal of Physiology, EarlyView.
Abstract figure legend FURIN induces vascular endothelial cell (VEC) death and efferocytosis through enzymatic cleavage of thrombospondin‐1 (THBS1). FURIN interacts with THBS1 to induce VEC apoptosis and efferocytosis, resulting in increased endothelial permeability.
Runji Chen, Daifei Shen, Amandine Mahieux, Dedrick Song, Shiwan Wu, Xiaoxin Huang, Xu Yang, Kunwei Chen, David G. McVey, Elisa A. Liehn, Roshni R. Singaraja, Shu Ye   +11 more
wiley   +1 more source

Blocking PCSK9 suppresses hepatocellular carcinoma immune escape by decreasing FLI1-mediated SPP1 and PD-L1 expression

Journal for ImmunoTherapy of Cancer
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a newly identified immunosuppressive regulator, but its mechanism of suppressing antitumor immunity remains ambiguous.
Rong Zhang, Xuan Wang, Yue Dai, Min Hu, Ming Qin, Changpeng Hu, Wenjing Lai, Huyue Zhou, Chengsha Yuan, Yafeng Liu, Mengmeng Yang, Menglin Luo, Guobing Li   +12 more
doaj   +1 more source

Therapeutic Potential of Berberis vulgaris in Modulating Metabolic Syndrome Biomarkers: Mechanistic Insights and Functional Food Implications

Food Frontiers, Volume 7, Issue 4, July 2026.
ABSTRACT Barberry (Berberis vulgaris) has emerged as a promising functional food candidate for the management of metabolic syndrome due to its diverse bioactive constituents, particularly berberine. This review synthesizes current experimental and clinical evidence regarding its effects on glycemic control, lipid metabolism, blood pressure regulation ...
Fakhar Shahid, Ifrah Jabeen, Muhammad Inam‐ur‐Raheem, Amin Mousavi Khaneghah, Muhammad Abid, Rana Muhammad Aadil   +5 more
wiley   +1 more source

Epoxy Clerodane Diterpene Attenuates the Differentiated Adipocyte Hypertrophy and Enhances Mitochondrial Metabolism

ChemistryOpen, Volume 15, Issue 7, July 2026.
Epoxy Clerodane Diterpene (ECD) significantly reduces adipocyte hypertrophy and lipid accumulation in human mesenchymal stem cell (hMSC)‐derived adipocytes. ECD improves mitochondrial membrane potential (ΔΨm), increases thermogenic regulators (UCP‐1, PPARγC1α), decreases adipogenic markers (C/EBPα, PPARγ), and reduces inflammatory mediators (TNF‐α, NF ...
Sahar Abdulaziz AlSedairy, Pandurangan Subash‐Babu, Maha H. Alhussain, Manal Abdulaziz Binobead, Ali A. Alshatwi   +4 more
wiley   +1 more source

Cellular Heterogeneity During Arterial Aging

Aging Cell, Volume 25, Issue 7, July 2026.
Graphical abstract showing arterial cell subpopulations and their functional changes during aging. Transcriptomic profiling studies across species identify age‐associated endothelial, smooth muscle, fibroblast, and immune cell states characterized by inflammation, extracellular matrix remodeling, phenotypic switching, and cellular senescence ...
He Xu, Paul‐Lennard Mendez, Dimitri Kasakovski, Judith Sluimer   +3 more
wiley   +1 more source

Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A meta-analysis of randomized controlled trials.

PLoS ONE
BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of drugs used for the treatment of dyslipidemia. PCSK9 inhibitors have been shown to remarkably reduce cardiovascular events in patients at high risk, but data on ...
Lei Zhang, Yuan-Yuan Li, Xue-Hui Liu, Hong-Jun Liu, Qiang Xu   +4 more
doaj   +1 more source

Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Combining PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors with statins significantly lowers low‐density lipoprotein cholesterol and reduces cardiovascular events in patients with coronary heart disease versus statins alone ...
Linchan Yu, Boyang Xiang, Yuxin Ren, Yi Li, Jiaying Xie, Xiang Zhou   +5 more
doaj   +1 more source

Inadequate Response to PCSK9 Inhibitors

JACC: Case Reports
Suboptimal response to various proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) therapies has been reported in the literature; however, inadequate response to proprotein convertase subtilisin/kexin type 9 monoclonal antibodies and small interference RNA is rare to our knowledge.A 68-year-old woman with hypercholesterolemia (baseline low-
Tia Bimal, Tanesh Ayyalu, Maya S. Safarova, Sean Donahoe, Courtney Davila, Thomas Dayspring, Michael Shapiro, Eugenia Gianos   +7 more
openaire   +2 more sources